NYLIM
KRON

New York Life Investment Management’s Kronos Bio KRON Stock Holding History

New York Life Investment Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-78,457
Closed -$127K – 1305
2022
Q4 		$127K Buy
78,457
+8,844
+13% +$20.4K ﹤0.01% 1186
2022
Q3 		$233K Buy
69,613
+5,112
+8% +$23.1K ﹤0.01% 1159
2022
Q2 		$235K Buy
+64,501
New +$292K ﹤0.01% 1210

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

New York Life Investment Management's KRON Position: Q1 2023 in Review

New York Life Investment Management sold out of Kronos Bio (KRON) in Q1 2023, closing a stake of 78,457 shares — an estimated $127K sold.

New York Life Investment Management first reported a position in KRON in Q2 2022 and held it in 3 quarters. The position peaked at $235K in Q2 2022. 87 funds tracked by Wall St. Rank hold KRON as of Q1 2023.

  • New York Life Investment Management reported no remaining Kronos Bio position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 78,457 Kronos Bio shares in Q1 2023, an estimated $127K.
  • New York Life Investment Management first reported a position in Kronos Bio in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Kronos Bio position peaked at $235K in Q2 2022.
  • 87 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.